Integrum (INTEG) Q2 24/25 earnings summary

Executive summary

• Q2 results were disappointing, with net sales for Q2 2024/25 at SEK 21.8M, down 21% year-over-year, and a focus on improving commercial execution and market adoption, especially in the U.S. and select European markets.

• Strategic shift from a science-driven to a commercially focused organization, prioritizing key markets, product launches, and leadership changes including a new acting CEO and Chief Scientific Advisor.

• Emphasis on driving adoption of the FDA-approved above-knee product and defending its market position, with early traction in ecosystem strategy.

• Rebalancing of R&D portfolio to focus on projects with the highest ROI and market impact.

• First OPRA® Implant System procedure performed in the UK and US sales team expanded.

Financial highlights

• Net sales for Q2 were SEK 21.8 million, down 21% year-over-year; May–Oct net sales were SEK 40.2 million, a 16.1% decrease year-over-year.

• Operating profit was minus SEK 11.3 million, impacted by SEK -0.8M in unrealized currency effects; profit after tax was SEK -8.9M.

• Sequential revenue growth of 18% from the previous quarter, mainly from increased S1 procedures and Axor sales.

• Cash position at end of October was SEK 34.1 million, with an additional SEK 31.6M in accounts receivables.

• Gross margin improved to 80% (from 71% in Q2 last year); cost of goods sold decreased to SEK -4.4M.

Outlook and guidance

• No specific profitability timeline or forward guidance provided; focus remains on increasing revenue, improving EBIT, and achieving sticky, tangible revenue for market penetration.

• Ambition to increase CAGR above the current 26%.

• Ongoing efforts to collect health economic evidence to support payer discussions and drive adoption.

• Expansion into new markets including Ukraine, Turkey, Israel, and the UK; continued development in EMEA.

• Cash position and extended credit facilities expected to support working capital and expansion needs.